New drug reverses even 'untreatable' cancers
Published on 05-19-2010
Reovirus, which lives in human respiratory and gastrointestinal tracts without causing any symptoms, can help magnify the effects of radiotherapy in treating even the most advanced cancers, laboratory tests have shown.
Tumours shrank or stopped growing in every patient who underwent radiotherapy coupled with a new drug, Reolysin, which contains particles of reovirus.
One patient had a large tumour mass in a salivary gland which was reduced in size enough to be surgically removed after undergoing the treatment. Another who was close to death with a serious form of spreading skin cancer was still alive 17 months later.
A total of 23 patients with a range of solid tumours including lung, bowel, ovarian and skin cancers took part in the clinical trial. All had stopped responding to traditional therapies but were able to get some pain relief from radiation treatment.
The patients were given between two and six injections of Reolysin in escalating doses, combined with low or high dose radiotherapy.
The primary aim was to test whether the treatment was safe, but researchers also measured tumour responses for 14 patients. Tumours either shrank or stopped growing in every case, the scientists reported in the journal Clinical Cancer Research.
The side effects of the treatment were mild and typical of patients receiving radiotherapy alone.
Dr Kevin Harrington, the study leader from the Institute of Cancer Research in London, said: ''The absence of any significant side effects in this study is extremely reassuring for future trials in patients receiving radiotherapy with the aim of curing their cancer.''
The next step will be to investigate the effects of the treatment in patients with newly-diagnosed cancers that would normally be treated with radiotherapy alone, he said.
Dr Brad Thompson, president and chief executive of Oncolytics Biotech Inc, the Canadian manufacturers of Reolysin, said: ''We believe that this study clearly demonstrates that the combination of low dose radiation and Reolysin is well tolerated and that the very high response rate warrants further investigation.''
No comments:
Post a Comment